Today is International Women’s Day and we are proud to celebrate the achievements and contributions of all our female team members, without whom our company would quite simply not exist! It is still too rare
We are delighted to announce that Mariann Kasela has been appointed as Production Manager and will be responsible for the DiagMMR® production operations. Congratulations! Mariann has been with the company from the early days and
We are delighted to share our newly created video about Lynch syndrome and DiagMMR®! In this short 2-minute video we provide a summary of what Lynch syndrome is and how our newly developed functional assay
Business Finland, the government organization for innovation funding and trade, travel and investment promotion, has published a brochure on ‘Cancer Expertise from Finland’. The digital booklet showcases Finland as a global leader in cancer research
We are very happy that LS CancerDiag has been selected to be part of the first cohort of the X-Europe programme – HealthTech, MedTech and BioTech! LS CancerDiag is proud to have been selected from the
We are delighted to announce that LS CancerDiag has been selected as a participant to the EIT Health Bridghead Global programme! The Bridgehead programme provides European start-ups and scale-ups with individualised support in growing their
Back in January when we were living in a different world, our CBO Philippe Arnez talked with Logan Plaster at the StartUp Health Festival in San Francisco. You can watch the full interview below which
Lynch syndrome. Even though it is the most common hereditary cancer syndrome in the world, it is mostly unknown. Lynch syndrome prevalence is currently estimated at 1 in 279 globally[1], meaning that in Europe alone
We are living through truly unprecedented times. As a company we are taking all the necessary precautions to keep our employees safe, while continuing to serve our customers. However, we also want to take a
LS CancerDiag gets the patent granted in Brazil for its innovative DiagMMR® test. The largest country in Latin America completes the already impressive patent portfolio of LS CancerDiag. Brazil brings the total count to 29
LS CancerDiag has launched a funding round in collaboration with Springvest.
The company aims to raise €5.4M in capital to support the expansion into the United States and introduce DiagMMR® to the largest health care market in the world.
